Sanofi, Regeneron Win U.S. Approval for Cancer Medicine

Sanofi and Regeneron Pharmaceuticals Inc. won U.S. clearance for Zaltrap as a treatment for patients with advanced colorectal cancer who haven’t been helped by previous therapy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.